Discovering and improving novel peptide therapeutics.

Cyclogenix Limited, Crombie Lodge, Aberdeen Science & Technology Park, Aberdeen, UK.
Current Opinion in Pharmacology (Impact Factor: 4.23). 08/2008; 8(5):616-9. DOI: 10.1016/j.coph.2008.06.002
Source: PubMed

ABSTRACT Peptides have a number of advantages over small molecules in terms of specificity and affinity for targets, and over antibodies in terms of size. However, sensitivity to serum and tissue proteases coupled with short serum half-life has resulted in few recombinant library derived peptides, making the transition from lead to drug on the market. Recently, a series of technologies have been developed to address both these issues: selection methodologies addressing protease resistance have been developed that when combined with methods such as pegylation antibody Fc attachment and binding to serum albumin look likely to finally turn therapeutic peptides into a widely accepted drug class.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Despite increasing demands within the healthcare market, the growth of peptide based therapeutic products is challenged by the need for sustainable processing strategies using cheaper and eco-friendly processes. To overcome this hindrance, this study aims to evaluate the potential of the intein autocleavage based bioprocessing platform as an alternative to the solid phase peptide synthesis (SPPS) route for economical peptide manufacture. The robustness of the bioprocessing strategy was evaluated by designing a processing platform for manufacturing an 11-mer synthetic antimicrobial peptide. The peptide was successfully produced in its active form using the SspDnaB mini intein system and showed antimicrobial efficacy against E. coli, a common pathogen. The cleaved peptide and the cleavage reaction was further characterized by RP-HPLC, MALDI-TOF mass spectrometry and calorimetric methods. Process simulation studies were also conducted using the Super Pro Designer software to compare the overall process economics and environmental impact of the proposed bioprocessing strategy with the SPPS methodology. Operating costs for the intein based bioprocessing strategy was found to be at least two to three times cheaper compared to the SPPS method while being 5-8 times more environmentally friendly.
    RSC Advances 01/2014; 4(60):31564. DOI:10.1039/C4RA04056B · 3.71 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A novel method has been developed for the efficient formation of peptide disulfide bonds under aqueous conditions using N-chlorosuccinimide. Complete disulfide bond formation is achieved in 15 min with solvent mixtures containing water and acetonitrile.
    RSC Advances 01/2013; 3(34):14277. DOI:10.1039/c3ra43149e · 3.71 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Pituitary adenylate cyclase activating polypeptide (PACAP) is a neuroendocrine factor that activates both the receptor VPAC1 and VPAC2. Although PACAP possesses insulinotropic activity, its therapeutic application is limited by the extremely short acting half-life and the stimulatory effects on glucagon production via a VPAC1-dependent mechanism. Here we have generated a recombinant PACAP-derived peptide (named as MHDBAY) comprising a 7-mer albumin-binding peptide identified by phage display screening (WQRPSSW), a cleavage peptide for Factor Xa (FXa) and dipeptidyl peptidase IV (DPP IV), and a 31-amino acid PACAP-derived peptide (DBAY) that can specifically bind to the VPAC2 receptor. MHDBAY binds to albumin both in vitro and in animals, thereby leading to an orderly slow release of the active peptide DBAY via the protease cleavage. In db/db mice and New Zealand rabbits, the circulating half-life of MHDBAY is approximately 12.2 h, which is 146-fold longer than DBAY (∼5 min). A single injection of MHDBAY into db/db diabetic mice markedly increases insulin secretion, thereby leading to sustained alleviation of hyperglycemia. The potency and duration of MHDBAY in increasing insulin secretion and decreasing blood glucose levels is much greater than Exendin-4, an anti-diabetic drug via its insulinotropic actions. Furthermore, chronic administration of MHDBAY by daily injection for 8 weeks significantly improves both glucose and lipid profiles and also greatly increases insulin sensitivity in db/db mice. These findings suggest that serum albumin may act as a reservoir for slow-release of small bioactive peptides, and MHDBAY may represent a promising therapeutic peptide for diabetes. Copyright © 2015 Elsevier Ltd. All rights reserved.
    Biomaterials 05/2015; 51. DOI:10.1016/j.biomaterials.2015.01.064 · 8.31 Impact Factor